Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

被引:0
作者
Yang, QF
Sakurai, T
Mori, I
Yoshimura, G
Nakamura, M
Nakamura, Y
Suzuma, T
Tamaki, T
Umemura, T
Kakudo, K
机构
[1] Wakayama Med Univ, Sch Med, Kihoku Hosp, Dept Surg, Wakayama, Japan
[2] Wakayama Med Univ, Sch Med, Dept Pathol 2, Wakayama, Japan
[3] Shandong Univ, Qilu Hosp, Dept Surg, Jinan, Peoples R China
关键词
sporadic breast carcinoma; BRCA1; immunohistochemistry; prognosis;
D O I
10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. BRCA1 is a tumor suppressor gene that is responsible for hereditary breast and ovarian carcinoma syndrome. The primary objective of the current study was to investigate the influence of BRCA1 expression on the prognoses of sporadic breast carcinomas. METHODS. A cohort of 175 Japanese women with invasive breast carcinoma who had no family history in first-degree relatives was studied. Expression of BRCA1 was determined by an immunohistochemical procedure in which the MS110 monoclonal antibody was used. Kaplan-Meier and Cox proportional regression survival analyses were used to compare negative and positive BRCA1 patients. RESULTS. One hundred fifteen (65.7%) of the 175 specimens showed positive BRCA1 staining (> 10% cells were immunoreactive). During a median follow-up of 4.4 years, negative BRCA1 patients had worse disease free survival than positive BRCA1 patients (35% vs. 7%, respectively; P < 0.0001). BRCA1 expression was significantly inversely correlated with histologic grade (P < 0.0001) but not with lymph node status or other conventional prognostic markers. In multivariate analysis using the Cox regression model, positive BRCA1 emerged as an independent prognostic indicator for disease free survival. CONCLUSIONS. The results of this study suggest that BRCA1 may be a valuable marker for identifying women with sporadic breast carcinoma at high risk of developing recurrence, and who may be candidates for trials investigating new therapies in combination with standard adjuvant therapy. Cancer 2001;92:54-60. (C) 2001 American Cancer Society.
引用
收藏
页码:54 / 60
页数:7
相关论文
共 41 条
[1]  
[Anonymous], 1994, CANC FACTS FIG
[2]  
[Anonymous], 1981, HIST TYP BREAST TUM
[3]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[4]   Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer [J].
Bianco, T ;
Chenevix-Trench, G ;
Walsh, DCA ;
Cooper, JE ;
Dobrovic, A .
CARCINOGENESIS, 2000, 21 (02) :147-151
[5]   Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes [J].
Cameron, DA ;
Keen, JC ;
Dixon, JM ;
Bellamy, C ;
Hanby, A ;
Anderson, TJ ;
Miller, WR .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (07) :845-851
[6]   Transcriptional activation by BRCA1 [J].
Chapman, MS ;
Verma, IM .
NATURE, 1996, 382 (6593) :678-679
[7]   Expression of BRCA1 and BRCA2 in normal and neoplastic cells [J].
Chodosh, LA .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1998, 3 (04) :389-402
[8]   DRUG-TARGET INTERACTIONS - ONLY THE 1ST STEP IN THE COMMITMENT TO A PROGRAMMED CELL-DEATH [J].
DIVE, C ;
HICKMAN, JA .
BRITISH JOURNAL OF CANCER, 1991, 64 (01) :192-196
[9]  
Dobrovic A, 1997, CANCER RES, V57, P3347
[10]  
Eisinger F, 1996, CANCER RES, V56, P471